A few weeks ago, someone in our community Reset posted a video in our group chat.
The message was straightforward: "The guys in this video are talking about injecting peptides for muscle gain, skin, and anti-aging. Can doctors in the group talk about the safety of these things?"
Another member replied: "Peptides have suddenly become a trend on fitness TikTok and Instagram too. I think most of it is centred around BPC-157."
Then, that same week, a friend sent me a post on Instagram from Nick Trigili (@realnicktrigili).
Four shirtless photos of celebrities labelled "Insulin Resistant," followed by a three-step protocol: get your bloodwork, fix your nutrition and training, then inject a stack of peptides and TRT to "multiply your results by 2-3x."
My friend's message was one word: "Thoughts?"
I looked at the post properly.
The bloodwork markers were real. The lifestyle advice was solid.
And then Step 3 listed four compounds: TRT, Retatrutide (listed as "R3TA"), Tesamorelin, and MOTS-c.
The closing line: "Can you do it completely naturally? Sure, but I personally won't."
When your own community is asking about safety, and friends are sending you the same content independently, it stops being a trend you can scroll past. So I went and read the research. Not the captions. Not the podcast clips. The actual clinical trials.
Here's what I found.
The Problems In Your Body Are Real - But Are Peptides The Solution?
Let me be clear about something before I go further: the metabolic problems these peptide influencers are describing are not made up.
Insulin resistance is quietly wrecking the health of millions of people in their 30s, 40s, and 50s.
Your fasting glucose can look "normal" on a blood test for a decade while your body compensates by producing more and more insulin just to keep that number in range.
By the time your glucose actually rises, the damage has been compounding for years.
That part, they get right.
What they get wrong is the leap from "this is a real problem" to "therefore you need to inject an unregulated compound that hasn't finished clinical trials."
What the Evidence Actually Says About Common Peptide Protocols
I looked at each compound in Trigili's protocol. Here's what the research says when you strip away the marketing language.
BPC-157 has the most preclinical data of any peptide in the influencer ecosystem.
The animal studies on tissue repair are genuinely impressive. But after 30 years of research, fewer than 30 human subjects have been studied across all published trials. A 2025 systematic review in HSS Journal screened 544 articles and found 35 preclinical studies and just 1 clinical study [1]. And nearly all of that research comes from a single lab group in Croatia, led by Dr. Predrag Sikiric. A 2025 scoping review flagged the possibility of publication bias, noting that virtually every published BPC-157 study reports positive results [2]. When one lab produces all the positive data for three decades and nobody else replicates it at scale, that is not how robust science works.
Retatrutide (R3TA) is a triple receptor agonist being developed by Eli Lilly.
The Phase 2 trial data showed roughly 24% body weight loss at the highest dose over 11 months, which is more than any currently approved weight-loss medication [3]. The mechanism is well understood and the science is real. But the compound is not FDA-approved. Drugs.com states plainly: any products currently sold as retatrutide are not legitimate and are illegal [4]. The version people are buying online is not the Eli Lilly trial compound. It is a copy manufactured in an unregulated facility, sold with a "research use only" label, with no guarantee that what's in the vial matches what's on the label.
Tesamorelin is the one with the strongest evidence. It is FDA-approved, but specifically for HIV-associated lipodystrophy.
A randomised trial of 412 patients published in the New England Journal of Medicine showed visceral fat decreased by 15.2% in the treatment group [5]. It works for visceral fat reduction. But a separate analysis published in Clinical Infectious Diseases showed it had a neutral effect on insulin resistance measures [6], which directly contradicts how it is being positioned in Trigili's protocol as part of an "Insulin Resistance Stack." It does one thing well. It doesn't do the thing they're selling it for.
MOTS-c has never been clinically tested in humans as a therapeutic peptide.
USADA (the US Anti-Doping Agency) states: "Currently it is unknown under what conditions, if any, it is safe to use MOTS-c because there are no completed clinical trials" [7]. The data is from mice. Mice are not people.
TRT (testosterone replacement therapy) does have evidence showing it can improve insulin sensitivity in men with clinically diagnosed hypogonadism.
But Trigili's post frames it as a metabolic optimisation tool, not a hormone replacement for a clinical deficiency. TRT carries documented risks including polycythaemia, cardiovascular complications, fertility suppression, and lifelong dependency. Describing it casually alongside supplements, as my friend put it, "as if it's a supplement," is not a small thing.
The Sales Funnel Behind Peptides You're Not Seeing
Here's what I noticed about how Trigili's protocol is structured. It follows the same pattern as every peptide sales funnel I've seen.
Step 1 gives you real bloodwork markers. Fasting glucose, fasting insulin, HbA1c, HOMA-IR. These are legitimate diagnostic tools. This step builds your trust because the science is real.
Step 2 gives you lifestyle advice. Sleep, weight training, walking, protein intake, sauna, cold exposure. Again, evidence-backed. Again, building trust.
Step 3 is where they sell you the peptide stack. And the bridge between Step 2 and Step 3 is: "Once you have these in place, here's the stack to multiply your results by 2-3x."
That 2-3x claim has no citation. Because it was made up. If you actually did everything in Step 2 consistently, you would not need Step 3.
The lifestyle slide is the real protocol. The peptide slide is the product.
The Peptide Supply Chain Nobody Talks About
Most of these peptides are manufactured in industrial clusters across Guangdong, Henan, and Zhejiang provinces in China, sold as bulk powder on B2B marketplaces, reconstituted by US-based companies, and labelled "for research use only" [8].
Independent testing by Finnrick (a peptide purity testing organisation) has shown massive variation in quality between suppliers, rating the same compound from two different suppliers as an "A" and an "E" respectively [9].
The "for research purposes only" disclaimer is not a quality assurance. It is a legal shield.
A CNN investigation in November 2025 reported that one peptide user group on Facebook instructs its members to say they are "researching" peptides rather than "taking" them, to avoid regulatory attention [10].
The FDA has sent over 100 warning letters to companies in this space [11]. MIT Technology Review reported that two women were hospitalised and put on ventilators after receiving peptide injections at a longevity conference in Las Vegas in 2025 [12].
What Actually Works for Insulin Resistance
I'm not going to pretend the answer is exciting. It isn't. But it is evidence-based.
Get the right blood tests.
Not just fasting glucose. Ask for fasting insulin (you want it under 8 μIU/mL, not the lab's generous "under 25" range). Ask for HbA1c (under 5.3%, not just under 5.7%). Calculate your triglyceride-to-HDL ratio (under 2 is a cheap proxy for insulin sensitivity that most doctors never bother with).
Do the basics consistently.
Weight training 3-5 times a week improves insulin sensitivity directly through GLUT4 transporter upregulation in muscle tissue. Walking 10,000+ steps keeps baseline glucose disposal high. Zone 2 cardio improves mitochondrial fat oxidation. Low sugar, adequate protein, no liquid calories. Sleep 7-9 hours. These are not novel ideas, but most people recommending peptides have never done all of them consistently for six months.
Consider what's actually been studied in humans.
Berberine has legitimate clinical evidence for improving insulin sensitivity and glucose metabolism through AMPK activation. It has been studied in real human trials, with real dosing data, in real clinical settings. It is not glamorous. Nobody is going to hold up a berberine capsule on Instagram and get 400,000 likes. But the evidence is there, published, replicated by multiple independent research groups, and available for anyone to read.
The Question Nobody's Asking
The influencer holds up the vial.
He tells you it changed his life. He tells you the FDA is suppressing it.
He tells you to do your own research.
But "do your own research" doesn't mean watching his next video.
It means looking for randomised controlled trials.
It means asking how many human subjects were studied.
It means checking whether the positive results come from one lab or from independent replication.
It means asking why a compound that's been researched since 1993 still has fewer than 30 human subjects in its entire published literature.
Someone in our community asked if doctors could talk about the safety of these things.
That's the right instinct. The metabolic problems are real. Your insulin resistance is real. The question is whether the solution should come from a vial with a "research use only" label, manufactured in an unregulated facility, sold through an affiliate link, or from the evidence that already exists.
I know which one I'd choose. But then again, I spent 13 months making sure the thing I put my name on could survive that question.
Sources
[1] Vasireddi N, et al. "Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review." HSS Journal, 2025. 544 articles screened, 35 preclinical and 1 clinical study included.
[2] "BPC-157: What a Psychiatrist Wants You to Know." Dr. Baghel, TheBH.us, March 2026. Flags publication bias in BPC-157 literature.
[3] Jastreboff AM, et al. Retatrutide Phase 2 clinical trial. Summarised by GoodRx, December 2025. 23-24% body weight loss at highest doses over ~11 months.
[4] Drugs.com. "Retatrutide: What is it and is it FDA approved?" Updated March 2026.
[5] Falutz J, et al. "Metabolic Effects of a Growth Hormone-Releasing Factor in Patients with HIV." New England Journal of Medicine. 412-patient RCT showing 15.2% visceral fat reduction.
[6] Stanley TL, et al. "Reduction in Visceral Adiposity Is Associated with Improved Metabolic Profile in HIV-Infected Patients Receiving Tesamorelin." Clinical Infectious Diseases, 2012.
[7] USADA. "What is the MOTS-c peptide?" January 2024.
[8] Accio/Alibaba supplier directories. "BPC 157 Wholesale: Premium Peptide Supplier for 2025." Documents manufacturing clusters in Guangdong, Henan, Zhejiang, and Fujian provinces.
[9] Finnrick peptide testing database, 2024-2026. BPC-157 quality ratings across suppliers range from A (Great) to E (Bad).
[10] CNN. "The trend of unproven peptides is spreading through influencers and RFK Jr. allies." November 15, 2025.
[11] RAPS. "FDA posts more than 100 warning and untitled letters in ad crackdown." September 2025.
[12] MIT Technology Review. "Peptides are everywhere. Here's what you need to know." February 24, 2026.
Share this post